Jyong Biotech (MENS) Common Equity (2024 - 2025)
Jyong Biotech (MENS) posted quarterly Common Equity of -$24.9 million for Q4 2025, up 31.8% year-over-year from -$18.9 million in Q4 2024, and down 10.83% quarter-over-quarter from -$22.5 million in Q2 2025.
Jyong Biotech (MENS) Common Equity (2024 - 2025) Analysis & Trends
Jyong Biotech's Common Equity history runs 2 years deep, the most recent figure standing at -$24.9 million for Q4 2025.
- In Q4 2025, Common Equity rose 31.8% year-over-year to -$24.9 million; the TTM figure through Dec 2025 stood at -$24.9 million (up 31.8% YoY), while the FY2025 annual figure was -$24.9 million, up 31.8% from the prior year.
- Common Equity for Q4 2025 stood at -$24.9 million, down from -$22.5 million in the prior quarter.
- The five-year high for Common Equity was -$22.5 million in Q2 2025, with the low at -$36.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Jyong Biotech | 159.89 Mn | 159.89 Mn | - | -24.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.91 Mn |
| Jun 30, 2025 | -22.47 Mn |
| Dec 31, 2024 | -36.52 Mn |